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 1
The challenge of treating cats with (presumed) allergic skin disease 1 
 2 
Introduction 3 
Feline dermatology presents a number of challenges; individual diseases can 4 
be problematic to diagnose due to the more subtle and varied nature of skin 5 
lesions in cats compared to those commonly seen in dogs. In feline allergic 6 
skin disease, the diagnostic challenge is increased further because cats 7 
present with one or more of four patterns of disease rather than the more 8 
typical character and distribution of lesions seen with canine hypersensitivity 9 
dermatoses. Cats are also generally more solitary animals and secretive in 10 
their behaviour, which can lead to the absence of important clues in the 11 
clinical history. In terms of treatment of allergic skin disease there can be 12 
challenges both in the administration of treatment and in the comparatively 13 
poor treatment responses seen in some patients.  14 
 15 
This article reviews the important steps in achieving a diagnosis of and 16 
successfully managing feline allergic skin disease, with particular reference to 17 
head and neck excoriations/pruritus which can be one of the more challenging 18 
presentations of feline allergic skin disease to manage. 19 
 20 
Disease pathogenesis 21 
 22 
Unlike canine disease, feline allergic skin disease (FASD) is poorly 23 
understood. The term feline atopic dermatitis is avoided by some 24 
dermatologists due to uncertainty about the significance of IgE in the 25 
development of skin lesions. What is known is that the histological pattern of 26 
cutaneous inflammation that develops in cats with hypersensitivity dermatitis 27 
is similar to that seen in humans and dogs. FASD is thought to develop, as in 28 
human and canine disease, in association with internal (genetic) predisposing 29 
factors and external stimuli. The proposed major external ‘triggers’ of disease 30 
flares include flea saliva, food and environmental allergens and result in 31 
clinical signs associated with flea bite hypersensitivity dermatitis (FBHD), 32 
food-induced hypersensitivity dermatitis (FIHD; cutaneous adverse food 33 
reaction) and non-flea, non-food-induced hypersensitivity dermatitis 34 
(NFNFIHD; feline atopic dermatitis), respectively. One study reported that 35 
25% of cats with NFNFIHD had concurrent food allergy, flea allergy or both 36 
(Halliwell 1997). It is also likely that a form of FASD, similar to canine atopic-37 
like dermatitis and human intrinsic atopic dermatitis, exists, in which an 38 
external allergenic trigger cannot be identified but clinical signs persist despite 39 
elimination of other differential diagnoses of pruritus. Contact dermatitis, 40 
another type of FASD, is not covered in this article, as it is uncommon 41 
compared to the other forms and presents with a more distinctive set of skin 42 
lesions that are associated with direct contact with an offending substance. 43 
 44 
The diagnosis of feline allergic skin disease 45 
 46 
In order to achieve long-term success in the management of FASD, it is 47 
essential that an accurate diagnosis be made. The diagnosis of FASD is a 48 
clinical one; it is made based on compatible history and physical examination 49 
findings and diagnostic tests are then performed to eliminate differential 50 
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 2
diagnoses. The most of common of these being ectoparasite infestation and 1 
microbial infection. Finally, diagnostic trials muste be performed to identify the 2 
type of allergic skin disease or more specifically, the trigger for the 3 
hypersensitivity dermatitis. The major steps in achieving a definitive diagnosis 4 
of FASD are shown in Figure 1.  5 
 6 
The diagnostic challenge in cats is in making the clinical diagnosis. A typical 7 
history includes a young age of onset (6 months – 32 years; approximately 8 
75% cases), presence of pruritus, lack absence of contagion (except for some 9 
cases of FBHD) and response to appropriate doses of glucocorticoids. 10 
Unfortunately, for many cases of FASD, the most important of these historical 11 
clues are not present as cats may present later in life,  and the owners have 12 
not observed self-trauma due to the secretive nature of cats and/or signs of 13 
flea infestation have not been observed as cats are highly efficient groomers. 14 
FBHD presents at any age and FIHD, although more common in young cats, 15 
can develop in mature cats (4-5 years old) and rarely in kittens and geriatric 16 
cats. Where owners have not observed self-trauma, the following signs 17 
provide evidence of pruritus: presence of linear excoriations (especially 18 
around the head and neck), broken hair shafts in areas of reduced coat 19 
density (this may need to be confirmed microscopically), increased incidence 20 
of hair balls and hairs embedded in the gingival sulci and/or dorsal tongue. 21 
 22 
Unlike canine atopic dermatitis that usually presents with clear evidence of 23 
pruritus and lesions very typical in their character and distribution, cats with 24 
FASD present with one or more of four disease patterns. These include head 25 
and neck excoriations/pruritus (HNEP; Figures 2 and 3), symmetrical self-26 
induced alopecia (Figures 4 and 5), miliary dermatitis and lesions of the 27 
eosinophilic granuloma complex (eosinophilic or indolent ulcer; Figure 6, 28 
eosinophilic plaque; Figure 7, eosinophilic granuloma; Figure 8). The major 29 
skin lesions associated with the patterns are summarised in Table 1. 30 
 31 
Identification of one or more of the four patterns increases the suspicion of 32 
FASD but does not confirm it, nor does it inform the clinician as to the 33 
underlying trigger. In 2012, Favrot and others published two sets of diagnostic 34 
criteria to assist in making a clinical diagnosis of non-flea induced 35 
hypersensitivity dermatitis (i.e. FIHD or NFNFIHD); the first set is for cats 36 
presenting with pruritus and the second for pruritic cats follo ing elimination 37 
of FBHD (Table 2). Clinically, FIHD and NFNFIHD are indistinguishable and 38 
despite the availability of the diagnostic criteria, differential diagnoses should 39 
still be carefully eliminated. The major differential diagnoses and diagnostic 40 
tests used to eliminate them are also summarised in Table 1. Uncommonly in 41 
FASD, sneezing, conjunctivitis, chronic coughing and/or feline asthma may be 42 
present in addition to skin lesions and gastrointestinal signs can be present 43 
more commonly in cats with FIHD. 44 
 45 
In all cases of suspected FASD a strict flea control trial and elimination diet 46 
must be performed to rule out FBHD and FIHD respectively. This is 47 
particularly important in cats presenting with HNEP as a large multicentre 48 
study by Hobi and others (2011) reported that 38% and 64% of cats 49 
presented with neck and facial lesions in association with FBHD and FIHD 50 
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 3
respectively. Suspected cases that have failed to respond to an initial trial 1 
should therefore, undergo a second trial. 2 
 3 
The elimination diet should involve feeding a novel protein and carbohydrate 4 
for 6-8 weeks. If the full dietary history is unknown a hydrolysate diet may 5 
have to be used. It can be very challenging to perform an appropriate trial due 6 
to some cats being particular about what they eat and cats with outdoor 7 
access being fed by neighbours and/or the local wildlife. In these cases a 8 
selection of diets may need to be trialed and the cat may need to be gradually 9 
weaned onto the new diet. Cats that have access to food out of doors may 10 
need to be restricted to the house for the duration of the trial, although this 11 
can produce further problems if the stress induced by the change in 12 
environment exacerbates the allergic skin disease or leads to behavioural 13 
overgrooming. In addition, further undesirable outcomes including 14 
inappropriate urination, aggression and feline lower urinary tract disease may 15 
result from changes to the cat’s environment. 16 
 17 
The flea control trial should include use of an adulticide with rapid flea 18 
knockdown in both the affected cat and all in contact animals, plus treatment 19 
of the environment with a combined adulticide and insect growth regulator for 20 
6-8 weeks. For cats with intermittent episodes of disease the length of both 21 
trials should be chosen to span a period over which clinical signs are 22 
expected to develop based on the history. 23 
 24 
Management 25 
The management of FASD is life long and can be broadly split into four 26 
treatment categories that aim to target the suspected pathogenesis. These 27 
include allergen avoidance and allergen specific immunotherapy (ASIT), anti-28 
inflammatories and immunomodulators, avoidance of flare factors and skin 29 
barrier care. Treatment must be individualised and take into account patient 30 
factors including severity of disease, general health status, home environment 31 
(including risk of exposure to flea bites), predisposition to secondary microbial 32 
infections and tolerance of systemic and topical therapy. Client factors must 33 
also be considered and include financial constraints and ability to administer 34 
medications (including available time and physical constraints). 35 
 36 
Cats presenting with severe inflammatory skin lesions (eosinophilic plaques 37 
and granulomas) and/or cats with severe pruritus and self trauma (HNEP) will 38 
require an initial focus on anti-inflammatory/immunomodulatory treatments to 39 
bring their skin lesions under control. For welfare reasons this treatment may 40 
need to be started before completion of diagnostic trials and achievement of a 41 
definitive diagnosis. In these cases, rapidly acting anti-inflammatories such as 42 
glucocorticoids are very useful as they can be used in sufficient doses (see 43 
below) and duration (usually 2-4 weeks) to control the clinical signs at the 44 
start of the diagnostic trials then tapered before the end of the trials to 45 
determine if clinical signs recur.  46 
 47 
Once a definitive diagnosis is made and severe skin lesions have been 48 
brought under control, additional treatments can be added for long-term 49 
maintenance and systemic anti-inflammatory treatments can be tapered. In 50 
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 4
cats with severe disease such as those presenting with HNEP and lesions of 1 
the eosinophilic granuloma complex, long term use of systemic anti-2 
inflammatory/immunomodulatory treatment is often required. In these cases it 3 
is important to use enough treatment initially to bring the clinical signs under 4 
control then use additional treatments to try to reduce the dose and dose 5 
frequency of systemic drugs in the longer term. For example, topical 6 
glucocorticoids such as hydrocortisone aceponate can be used daily to treat 7 
flares of focal disease and on a twice weekly basis for known problem areas, 8 
alongside a tapered dose of the systemic treatment. 9 
 10 
The clinical benefit of polypharmacy has to be balanced with animal tolerance 11 
and owner compliance, but one of the main advantages of its use is the 12 
potential to reduce the dose, and therefore the risk of adverse effects, of 13 
potent systemic treatments. When planning a long-term management protocol 14 
for allergic skin disease, treatments from each of the four categories should 15 
be considered. 16 
 17 
Allergen avoidance and allergen specific immunotherapy (ASIT) 18 
Cases experiencing flares in association with flea bites or food should be 19 
managed long term by avoiding the offending allergen. In cases of FBHD, 20 
aggressive adulticidal flea control should be maintained for the affected 21 
animal, in contacts and the environment for life. For cases of FIHD, the 22 
offending food(s) should be determined via re-challenge with individual 23 
ingredients and avoided long term. In cases where these diseases have been 24 
ruled out, environmental allergen IgE serology or intradermal testing can be 25 
performed and where positive results are obtained, ASIT can be considered to 26 
try to reduce the incidence of disease flares associated with exposure to 27 
environmental allergens. Avoidance of environmental allergens is challenging 28 
and rarely successful due to the ubiquitous nature of these proteins. This 29 
treatment ASIT is generally well tolerated and appears to be safe for the long 30 
term management of NFNFIHD. The reported response rate is 50-75% 31 
(Roosje and others 2002), however, it is rarely not always successful as a 32 
sole form of therapy (most likely due to the complex pathogenesis of 33 
NFNFIHD) and as it can take up to 12 months to see the full effects, all cases 34 
will need anti-inflammatory/immunomodulatory treatment in their initial 35 
management plan. The reported response rate to ASIT is 50-75% (Roosje 36 
and others 2002) and it appears to be safe for long-term management of 37 
NFNFIHD. 38 
 39 
Anti-inflammatories and immunomodulators 40 
 41 
Glucocorticoids 42 
FASD, like allergic skin disease in other species, usually responds well to 43 
treatment with systemic glucocorticoids. Some feline cases, however, require 44 
high dosages and some can be refractory to treatment. Oral treatment with 45 
prednisolone at starting doses of 1-2 mg/kg once daily are usually effective, 46 
although in some cases higher doses of up to 4 mg/kg once daily can be 47 
required. A recent study by Ganz and others (2013) demonstrated that 48 
methylprednisolone at a mean dosage of 1.4mg/kg once daily for 1-2 weeks 49 
was a very effective and safe treatment in achieving remission. Cats were 50 
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 5
then maintained on 0.5 mg/kg every 48 hours. If the owner cannot administer 1 
tablets, injectable dexamethasone solution can be trialled. This is given by 2 
mouth or added to food at 0.1 mg/kg per day (induction dose) and 0.05 to 0.1 3 
mg/kg every 3 days (maintenance dose).  4 
 5 
Response to systemic glucocorticoids should be assessed every 7-14 days 6 
with the aim to maintain the cat on the lowest alternate day (or less frequent) 7 
dose that keeps disease in remission. If no response is seen, additional 8 
therapy should be considered in order to avoid excessive use of 9 
glucocorticoids. Where possible, depot corticosteroid preparations should be 10 
avoided due to the inability to withdraw treatment if adverse effects are 11 
encountered and, conversely, the inability to increase the dose if insufficient 12 
response is seen.  13 
 14 
Care must be taken with the long-term use of potent glucocorticoids due to 15 
the risk of adverse effects. A study of 14 cats treated daily with prednisolone 16 
or dexamethasone suggested that dexamethasone induces greater 17 
diabetogenic effects than equipotent doses of prednisolone (Lowe and others 18 
2009). Although cats seem to be more tolerant to systemic glucocorticoids 19 
than dogs, adverse effects including polydipsia, polyphagia, changes in 20 
weight, diabetes mellitus, urinary tract infection, iatrogenic 21 
hyperadrenocorticism, congestive heart failure, demodicosis and gastric 22 
ulceration can be seen. 23 
 24 
Ciclosporin 25 
Ciclosporin is a calcineurin inhibitor that exerts an immunomodulating effect 26 
via, amongst other actions, suppression of T lymphocyte function. It is 27 
licensed for use in cats in oral liquid form at 7 mg/kg once daily (Atopica Cat, 28 
Novartis Animal Health UK Ltd). A number of studies have demonstrated 29 
ciclosporin to be effective in the treatment of NFNFIHD and as effective as 30 
prednisolone (1mg/kg SID) at the licensed dose. As with dogs, once daily 31 
treatment should be continued for four weeks and if a good response is seen, 32 
treatment can be tapered to alternate day and then twice weekly therapy. 33 
Cats that relapse on alternate day therapy can be managed on daily 34 
treatment, reducing the dose to the lowest that maintains remission.   35 
 36 
Ciclosporin, used at the licensed dose, is well tolerated by most cats, with 37 
main adverse effects limited to mild gastrointestinal disturbances (Heinrich 38 
and others 2011). Some reports have suggested a link between cases of 39 
toxoplasmosis and neoplasia. The cited cases of neoplasia, however, 40 
occurred following immunosuppression with a combination of ciclosporin and 41 
prednisolone prior to renal transplantation. Treatment with prednisolone and 42 
ciclosporin may also increase the risk of toxoplasmosis, however, the disease 43 
appears to be rare at the licensed dose of ciclosporin. Toxoplasma-naïve cats 44 
may be at a slightly higher risk of developing clinical toxoplasmosis during 45 
treatment and preventative measures include avoiding raw meat, keeping cats 46 
indoors, and fitting two bells to a collar to make hunting less successful. 47 
Healthy serologically positive cats, however, don’t appear to be at risk of 48 
recrudescence of latent disease. Toxoplasma serology should therefore be 49 
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 6
considered prior to commencement of treatment, along with FIV and FeLV 1 
testing as per data sheet recommendations. 2 
 3 
Hydrocortisone aceponate 4 
Hydrocortisone aceponate (HCA) is a non-halogenated, double ester 5 
glucocorticoid licensed for topical use in dogs as a 0.0584% spray 6 
(Cortavance, Virbac Ltd). Unlike conventional topical glucocorticoids, HCA is 7 
metabolised within the skin into a largely inactive form, allowing it to maintain 8 
local potency without the risk of systemic adverse effects (Brazzini and 9 
Pimpinelli 2002). A recent study (Schmidt and others 2012) evaluated the 10 
efficacy of daily or alternate day application of the commercially available 11 
0.0584% HCA spray in ten cats with presumed allergic skin disease. There 12 
were significant improvements in both clinical lesion and pruritus scores over 13 
the 56-day study period. Ease of application of the spray, as scored by 14 
owners in the study, increased significantly with time and most owners rated 15 
the drug’s efficacy as good or excellent. During the study, two sprays of HCA 16 
were applied to a 10 x 10 cm area of lesional skin daily for 28 days and 17 
reduced to alternate day therapy if there was a greater than 50% 18 
improvement in clinical lesion and pruritus scores. The response to treatment 19 
was rapid and most of the clinical improvement was seen within 14 days. Only 20 
one cat was withdrawn from the study due to poor treatment efficacy and no 21 
adverse effects were reported in any of the cats. The study suggests HCA is 22 
effective and safe for the treatment of FASD, although further controlled 23 
studies are required. 24 
 25 
Oclacitinib 26 
Oclacitinib is a novel drug that inhibits cytokines involved in allergic skin 27 
inflammation and pruritus via the inhibition of Janus kinase (JAK) enzymes. It 28 
is licensed for the treatment of canine atopic dermatitis at 0.4-0.6mg/kg twice 29 
daily for 14 days then once daily for maintenance therapy (Apoquel, Zoetis). A 30 
recent pilot study reported efficacy in a small number of cats with NFNFIHD, 31 
treated at the licensed dose for dogs over 28 days (Ortalda and others 2015). 32 
There was a reduction in skin lesions and pruritus scores in 6/12 and 5/12 33 
cats respectively. No adverse effects were reported and owners judged ease 34 
of administration as good or excellent. This small study suggests that 35 
oclacitinib may be an option for the treatment of some cats with NFNFIHD, 36 
however, licensed treatments with a greater strength of evidence for efficacy 37 
should be prioritised. Due to the lack of long-term treatment data, and as per 38 
datasheet recommendations for long-term treatment in dogs, periodic 39 
monitoring of complete blood count and serum biochemistry should be 40 
performed. 41 
 42 
Interferon omega 43 
Anecdotal reports suggest that twice weekly or weekly subcutaneous 44 
injections of 2.5MU interferon omega (Virbagen, Virbac Ltd) can be effective 45 
and well tolerated in some cats with FASD. The mode of action is unknown, 46 
but is thought to be immunomodulatory. However, only a few cats have been 47 
treated and the long-term safety and efficacy is unknown. Interferon omega 48 
should therefore be reserved for cases that have failed to respond to licensed 49 
treatments with proven efficacy. 50 
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 1 
Progestagens 2 
Megoestrol acetate (Ovarid, Virbac Ltd) is licensed for the management of 3 
lesions associated with FASD. Due to the risk of severe adverse effects 4 
including weight gain, diabetes mellitus, adrenocortical suppression, pyometra 5 
and mammary hyperplasia, and the availability of safer, more efficacious 6 
drugs, its use is not recommended. 7 
 8 
Avoidance of flare factors 9 
Flare factors are anything capable of exacerbating pruritus in animals with 10 
allergic skin disease. They include parasitic infestations, microbial infections, 11 
extremes of temperature/humidity and stress/anxiety (e.g. changes in the 12 
home environment). Although secondary microbial infections are known to be 13 
less common in FASD as compared to canine and human disease, both 14 
secondary bacterial staphylococcal pyoderma and Malassezia dermatitis have 15 
been reported. All FASD cases presenting with flares of pruritus should 16 
therefore undergo skin surface cytology to assess for microbial 17 
overgrowth/infection and treated appropriately. Microbial overgrowths and 18 
superficial bacterial infections should be managed using topical antimicrobial 19 
therapy. Although cats may be less tolerant of bathing, they may be more 20 
accepting of antimicrobial wipes (e.g. CLX Wipes, Vetruus) and sprays (e.g. 21 
Vetericyn Plus, Innovacyn Inc.) applied via cotton wool. For cats prone to 22 
recurrent microbial overgrowths, regular use of topical antimicrobial therapy 23 
on a twice-weekly basis should help to reduce the frequency of infection. 24 
 25 
Skin barrier care 26 
Little is known about the role of skin barrier dysfunction in the development of 27 
FASD but it is thought, as with canine and human disease, to form part of the 28 
pathogenesis and steps should therefore be taken to improve skin barrier 29 
care. As above, topical therapy with skin soothing shampoos, moisturisers 30 
and humectants may be limited in cats and care needs to be taken with leave-31 
on therapies due to their meticulous grooming behaviour. Oral essential fatty 32 
acid supplementation can be trialled along with topical lipid complexes applied 33 
either with the use of a protective collar or to areas that the cat cannot groom. 34 
 35 
Conclusion 36 
There are a number of challenges with both the diagnosis and management 37 
of FASD. Identification of one or more of the patterns of FASD along with the 38 
use of Favrot’s criteria assist with the diagnosis but differential diagnosis must 39 
be carefully eliminated. In all cases, a robust flea control trial and elimination 40 
diet must be performed. In cases that are more challenging to manage e.g. 41 
those presenting with HNEP, further repeat trials may be considered if no 42 
response is seen in the first instance in order to be certain that these triggers 43 
are eliminated. Additionally, all cases of suspected FASD failing to respond to 44 
appropriate treatment should have their diagnosis reviewed and repeat or 45 
further investigations e.g. treatment trial for Demodex gatoi infestation should 46 
be considered. The approach to management of FASD should focus on the 47 
four treatment categories that target the main areas of disease pathogenesis. 48 
It is of great importance to bring severe pruritus and skin lesions under control 49 
with adequate therapy before switching to safe, lifelong maintenance therapy. 50 
Page 7 of 10
https://mc.manuscriptcentral.com/inpract
In Practice
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
 8
 1 
 2 
 3 
MCQs 4 
1) Which of the following is one of Favrot’s criteria that can be used to 5 
assist in the diagnosis of FASD in cats presenting with pruritus prior to 6 
the exclusion of FBHD? 7 
a. Presence of crusting over the face and neck 8 
b. Absence of erosions/ulcerations on the front limbs 9 
c. Presence of ulceration affecting the footpads 10 
d. Absence of nodules/tumours 11 
2) Which of the following body regions have been are commonly 12 
associated with both food-induced hypersensitivity dermatitis and flea 13 
bite hypersensitivity dermatitis? 14 
a. Ventral abdomen 15 
b. Face and neck 16 
c. Dorsal lumbosacral region 17 
d. Interdigital skin 18 
3) What is the main indication for performing allergy testing in cats? 19 
a. To confirm a diagnosis of feline non-flea, non-food induced 20 
hypersensitivity dermatitis (NFNFIHD) 21 
b. To confirm a diagnosis of food-induced hypersensitivity 22 
dermatitis (FIHD) 23 
c. Following a diagnosis of NFNFIHD to identify environmental 24 
allergens for avoidance 25 
d. Following a diagnosis of NFNFIHD to identify environmental 26 
allergens for used in allergen specific immunotherapy 27 
4) Which of the following drugs therapies are is licensed for use in cats for 28 
the management of FASD? 29 
a. CPrednisolone and ciclosporin 30 
b. Ciclosporin and Aallergen specific immunotherapy 31 
c. Hydrocortisone aceponate and prednisolone 32 
d. Ciclosporin and Ooclacitinib 33 
5) Which treatment group should be used initially in cats presenting with 34 
severe head and neck excoriations or pruritus? 35 
a. Allergen avoidance and allergen specific immunotherapy 36 
b. Anti-inflammatories and immunomodulators 37 
c. Avoidance of flare factors 38 
d. Skin barrier care 39 
 40 
Answers 41 
1) d 42 
2) b 43 
3) d 44 
4) a 45 
5) b 46 
 47 
 48 
 49 
References 50 
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